<DOC>
	<DOCNO>NCT00671632</DOCNO>
	<brief_summary>The purpose study determine relative abuse potential ramelteon , daily ( QD ) , compare triazolam subject history drug abuse .</brief_summary>
	<brief_title>Behavioral Subjective Efficacy Ramelteon Subjects With History Polydrug Abuse</brief_title>
	<detailed_description>Insomnia characterize complaint either difficulty initiate maintain sleep , nonrestorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask `` ever difficulty sleep . '' Based report `` regular '' `` frequent '' sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd. , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . Participation study anticipate 1 month .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Triazolam</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Must good health determine physician ( ie , via medical history physical examination ) . Clinical laboratory evaluation ( include clinical chemistry , hematology , complete urinalysis ) within reference range test laboratory unless result deem clinically significant investigator sponsor . Must history substance abuse dependence , commonly abuse recreational psychoactive drug ( e.g. , benzodiazepine , cocaine , opiates , cannabinoids ) . Must negative urine sample substance abuse negative breathalyzer test first dose study medication administer . Must free signs/symptoms withdrawal substance admittance research unit prior first dose study medication . Must report like study medication give Day 2 liking must great magnitude like study medication give Day 1 . Exclusion Criteria Known hypersensitivity ramelteon related compound include melatonin . Known hypersensitivity benzodiazepine relate compound . Current diagnosis type physical drug dependence nicotine caffeine . Positive HBsAg exclude . Positive human immunodeficiency virus antibody screen . Diastolic blood pressure great 90 mm Hg systolic pressure great 140 mm Hg screening . Previous history cancer , basal cell carcinoma , remission least 5 year prior first dose study drug . Body weight less 99 great 264 pound . Subjects morbidly obese define great 2 time ideal body weight Significant urine concentration drug could interfere study . Clinically significant abnormal find physical examination electrocardiogram . Subjects clinically significant illness past 30 day . Current Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised diagnosis serious psychiatric condition ( e.g . Schizophrenia , Major Depression ) . Currently participate another investigational study participate investigational study within past 30 day . Any serious disease condition screen randomization might affect life expectancy make difficult successfully manage follow subject accord protocol . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Addiction</keyword>
</DOC>